ArticleJAMA oncology2018

Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.

Vinay Prasad et al.PubMed ↗Publisher ↗

No numbers read from the abstract.